MarketBeat Compares Ironwood Pharmaceuticals and Exicure Target Prices
What happened
MarketBeat compared Ironwood Pharmaceuticals and Exicure, two small-cap healthcare companies. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 61.69%. The report noted that Ironwood Pharmaceuticals has higher revenue and earnings than Exicure, while Exicure trades at a lower price-to-earnings ratio.
From tickerreport.com
Why it matters
The comparison highlights differences in valuation and ownership structure between the two firms. Analysts favor Ironwood Pharmaceuticals due to its stronger consensus rating and higher probable upside, despite Exicure having a lower price-to-earnings ratio.
From tickerreport.com
Who's involved
- Ironwood PharmaceuticalsSmall-cap healthcare company whose consensus target price was reported
- NasdaqElectronic stock exchange where Ironwood Pharmaceuticals is listed
- Virtus Investment PartnersAsset management firm potentially affected by the investment data
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Virtus Investment PartnersSpeculative
Virtus Investment Partners might adjust its investment strategy based on the favorable rating for Ironwood Pharmaceuticals.
Keep exploring
The entities involved
-
Ironwood Pharmaceuticals
company in Cambridge, United States